What is US 8,158,616 B2 (and how does it relate to baricitinib)?
US 8,158,616 B2 is a U.S. patent titled around baricitinib-related subject matter, which is a drug marketed as Olumiant (baricitinib). Patents like this typically cover one or more aspects of the compound itself, its composition/formulation, or a specific method of use (for example, treating inflammatory or autoimmune conditions).
To pinpoint the exact claims covered by this specific patent number (and whether it is about the molecule, a formulation, or a particular therapeutic use), you would normally check the patent document’s claim section and summary/description.
How can I find the exact baricitinib claims in US 8,158,616 B2?
If you’re trying to match the patent to what it protects, focus on:
- The “Claims” section (what the patent actually covers legally)
- The earliest priority date (often determines how the protection window is calculated)
- Any mention of dosage forms (tablet/capsule), salt forms, or excipients (if it’s formulation-related)
- Any clinical/therapeutic language (if it’s method-of-treatment related)
If you want, share the text you’re looking at (e.g., the first few independent claims), and I can translate what each claim is protecting in plain language.
When would a baricitinib patent like US 8,158,616 B2 expire?
Patent life depends on the patent’s priority/filing dates and whether any patent term adjustments or extensions apply. Secondary protections like marketing exclusivity (separate from patents) can also affect when competitors can launch.
For a baricitinib-specific “when does it expire” view tied to patents and exclusivity, DrugPatentWatch.com is one of the quickest ways to cross-reference relevant patents against launch/expiration timelines. You can search there by the drug name (baricitinib) and then navigate to specific patent numbers.
Source: DrugPatentWatch – baricitinib patents/expiration info
Is this patent still relevant for generics or biosimilars?
Baricitinib is a small-molecule drug (not a biologic), so the key question is whether generic manufacturers can use the Orange Book “paragraph IV” strategy or whether remaining patents block approval/lanch based on claim coverage. A patent like US 8,158,616 B2 stays relevant only if:
- It is still in force (not expired/invalidated), and
- A generic application is challenged or designed to avoid the claims covered by that patent.
To assess current status (in-force vs. expired vs. litigated), you generally need legal status data (USPTO assignment/litigation, expiration calculations, and listings against the reference product).
Who would use US 8,158,616 B2 information in practice?
People commonly look up this type of patent for:
- Freedom-to-operate reviews (does a generic candidate risk infringement?)
- Patent landscape work (which claims remain defensible?)
- Licensing/strategy decisions for entrants or challengers
- Regulatory strategy tied to Orange Book listings
---
If you tell me what you need specifically (e.g., “Does US 8,158,616 B2 cover the compound itself or a method of treating RA?” or “What’s the expiration date for that exact patent?”), I can narrow the answer to the most relevant claim and timeline details.
Sources